Your browser doesn't support javascript.
loading
Pretreatment Fibrinogen Level Is a Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment.
Aoyama, Toru; Kato, Aya; Hashimoto, Itaru; Maezawa, Yukio; Hara, Kentaro; Kawahara, Shinnosuke; Kazama, Keisuke; Komori, Keisuke; Yoshizawa, Suzue; Tamagawa, Ayako; Tateishi, Minori; Minami, Tomoyuki; Cho, Haruhiko; Morita, Junya; Otani, Kazuki; Sawazaki, Sho; Numata, Masakatau; Tanabe, Mie; Oshima, Takashi; Saito, Aya; Yukawa, Norio; Rino, Yasushi.
Afiliación
  • Aoyama T; Department of Surgery, Yokohama City University, Yokohama, Japan; t-aoyama@lilac.plala.or.jp.
  • Kato A; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Hashimoto I; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Maezawa Y; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Hara K; Department of Surgery, Yokohama City University, Yokohama, Japan; ykzawa0@gmail.com.
  • Kawahara S; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Kazama K; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Komori K; Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Yoshizawa S; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Tamagawa A; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Tateishi M; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Minami T; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Cho H; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Morita J; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Otani K; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Sawazaki S; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Numata M; Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Tanabe M; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Oshima T; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Saito A; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Yukawa N; Department of Surgery, Yokohama City University, Yokohama, Japan.
  • Rino Y; Department of Surgery, Yokohama City University, Yokohama, Japan.
Anticancer Res ; 44(1): 249-255, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38159985
ABSTRACT
BACKGROUND/

AIM:

Pretreatment fibrinogen levels are a promising prognostic marker for some malignancies. The aim of the present study was to evaluate the clinical impact of fibrinogen levels before treatment in patients with esophageal cancer who underwent curative resection. PATIENTS AND

METHODS:

This study included 123 patients who underwent curative treatment for esophageal cancer between 2005 and 2020. The prognosis and clinicopathological parameters in the high fibrinogen and low fibrinogen groups were analyzed.

RESULTS:

Overall survival (OS) stratified by individual clinical factors was compared using the log-rank test, and a significant difference was observed when a pretreatment fibrinogen level of 400 g/dl was used as a cutoff value. The comparison of the patient background factors between the high fibrinogen (400 g/dl) and low fibrinogen (<400 g/dl) groups revealed significant differences in pathological T status and lymph node metastasis. In the low fibrinogen group, the OS rates at 3 and 5 years after surgery (71.4% and 58.1%, respectively) were significantly higher than those in the high fibrinogen group (38.3% and 32.4%, respectively). Univariate and multivariate analyses for OS showed that the fibrinogen level prior to treatment was a significant prognostic factor. Similar results were observed for recurrence-free survival. In addition, when the first recurrence site was compared, there were marginally significant differences in hematologic recurrence.

CONCLUSION:

Pretreatment fibrinogen levels are a significant risk factor in patients with esophageal cancer. Therefore, pretreatment fibrinogen levels are a promising prognostic factor for patients with esophageal cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas Límite: Humans Idioma: En Revista: Anticancer Res Año: 2024 Tipo del documento: Article Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas Límite: Humans Idioma: En Revista: Anticancer Res Año: 2024 Tipo del documento: Article Pais de publicación: Grecia